Upadacitinib in Active Non-radiographic Axial Spondyloarthritis: 1-Year Data From a Double-Blind, Randomized, Placebo-Controlled, Phase 3 Trial.
Filip E Van den BoschAtul A DeodharDenis PoddubnyyWalter P MaksymowychDésirée Mfm van der HeijdeTae Hwan KimKishimoto MitsumasaXenofon BaraliakosYihan LiKristin M D'SilvaPeter WungIn-Ho SongPublished in: ACR open rheumatology (2024)
Treatment with upadacitinib showed sustained efficacy versus placebo with no new safety findings identified through 1 year. These results support the continued favorable benefit-risk profile of upadacitinib treatment for nr-axSpA.